Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized Study to Evaluate the Rate of Nausea in Healthy Premenopausal Female Subjects Treated With a Single Dose of Bremelanotide Alone or With Zofran

Next Previous
Trial Profile

A Phase 1, Randomized Study to Evaluate the Rate of Nausea in Healthy Premenopausal Female Subjects Treated With a Single Dose of Bremelanotide Alone or With Zofran

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bremelanotide (Primary) ; Ondansetron
  • Indications Cognition disorders; Female sexual dysfunction
  • Focus Adverse reactions
  • Sponsors AMAG Pharmaceuticals

Most Recent Events

  • 02 May 2022 Data from two phase 1 studies this and other study assessing effects of bremelanotide's agonism at MC4R on caloric intake and body weight, published in the Diabetes, Obesity and Metabolism
  • 16 Jul 2020 Status changed from recruiting to completed.
  • 11 Jun 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top